Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
详细信息 查看全文
- 作者：D.A. Fennella ; df132@leicester.ac.uk" class="auth_mail" title="E-mail the corresponding author ; df132@le.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Y. Summersb ; Yvonne.Summers@christie.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; J. Cadranelc ; jacques.cadranel@aphp.fr" class="auth_mail" title="E-mail the corresponding author ; T. Benepald ; tim.benepal@stgeorges.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; D.C. Christophe ; daniel.christoph@uk-essen.de" class="auth_mail" title="E-mail the corresponding author ; R. Lalf ; Rohit.Lal@gstt.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; M. Dasg ; das_mayukh@lilly.com" class="auth_mail" title="E-mail the corresponding author ; F. Maxwellg ; fiona_maxwell@lilly.com" class="auth_mail" title="E-mail the corresponding author ; C. Visseren-Grulh ; visseren-grul_carla@lilly.com" class="auth_mail" title="E-mail the corresponding author ; D. Ferryg ; ferry_david@lilly.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Cisplatin ; Doublet regimens ; First-line ; Non-small cell lung cancer
- 刊名：Cancer Treatment Reviews
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：44
- 期：Complete
- 页码：42-50
- 全文大小：625 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Cisplatin is a mainstay component of doublet regimens for advanced NSCLC.
- class="label">•
Changes in practice have improved cisplatin tolerability.
- class="label">•
These include refined administration schedules and use of prophylactic agents.